United States Cardiovascular Devices Market to Reach USD 41.29 Billion by 2032, Says Vyansa Intelligence

NEW DELHI, March 13, 2026 /PRNewswire/ -- According to the latest research study published by Vyansa Intelligence, the Cardiovascular Devices Market in the United States is projected to grow at a CAGR of around 9.35% during 2026–2032. The market expansion is primarily attributed to the increasing prevalence of cardiovascular diseases, rapid technological advancements in minimally invasive cardiac procedures, and the growing adoption of advanced diagnostic and therapeutic cardiovascular devices across healthcare facilities in the country.

United States Cardiovascular Devices Market Key Takeaways

• The United States Cardiovascular Devices Market is estimated at around USD 22.08 billion in 2025 and is projected to reach approximately USD 41.29 billion by 2032, reflecting strong market growth supported by continuous technological innovation and rising cardiovascular healthcare needs.
• By device type, therapeutic and surgical cardiovascular devices are expected to dominate the market, capturing approximately 75% market share, driven by the increasing adoption of interventional cardiology procedures and cardiac implant technologies.
• By end user, hospitals are projected to maintain their leadership position with around 60% share, as they remain the primary centers for advanced cardiovascular diagnosis, treatment procedures, and device implantation.
• More than 10 companies are actively engaged in producing cardiovascular devices across the United States, indicating a competitive and innovation-driven market landscape.
• The top five companies collectively account for nearly 55% of the market share, including GE Healthcare, Siemens Healthineers, Stryker Corporation, Medtronic plc, and Abbott Laboratories, among others.

Major Drivers Supporting the Demand for Cardiovascular Devices Across the United States

• Rising Prevalence of Cardiovascular Diseases

Cardiovascular diseases remain one of the leading causes of mortality and morbidity in the United States. Conditions such as coronary artery disease, cardiac arrhythmia, and heart failure affect millions of individuals across the country. The growing prevalence of lifestyle-related risk factors, including obesity, diabetes, sedentary lifestyles, and hypertension, continues to increase the overall cardiovascular disease burden. As a result, healthcare providers are increasingly relying on advanced cardiovascular diagnostic and therapeutic devices to support early detection, accurate diagnosis, and effective treatment.

• Advancements in Minimally Invasive and Transcatheter Technologies

Technological innovation is playing a significant role in transforming cardiovascular treatment approaches across the United States. The growing adoption of minimally invasive and transcatheter procedures enables physicians to treat complex cardiovascular conditions with reduced surgical trauma, shorter hospital stays, and improved patient recovery outcomes. Technologies such as transcatheter heart valves, catheter-based interventions, and image-guided cardiac procedures are gradually replacing conventional open-heart surgeries in several clinical applications. Consequently, medical device manufacturers continue to invest in research and development to enhance device performance and procedural efficiency.

• Increasing Integration of Artificial Intelligence and Wearable Monitoring Devices

The integration of artificial intelligence, machine learning, and wearable monitoring technologies is further expanding the capabilities of cardiovascular care. AI-powered diagnostic tools are improving the accuracy of cardiac imaging analysis and risk assessment, while wearable cardiovascular monitoring devices allow continuous tracking of heart rhythms and vital parameters. These innovations support the growing shift toward preventive healthcare and remote patient monitoring, thereby contributing to broader adoption of cardiovascular devices across clinical and home care settings.

Key Industry Constraint Limiting Market Growth

• High Costs Associated with Advanced Cardiovascular Devices

Despite ongoing technological advancements, the high cost associated with advanced cardiovascular devices and procedures remains a key challenge for the market. Technologies such as robotic-assisted cardiac surgery systems, implantable cardiac devices, and transcatheter treatment solutions often require substantial capital investment for hospitals and healthcare institutions. Additionally, regulatory approval requirements and stringent quality standards can increase product development timelines and manufacturing costs, which may limit the adoption of certain advanced cardiovascular technologies in some healthcare settings.

View Full Report and request to get the sample pages at:
https://www.vyansaintelligence.com/industry-report/united-states-cardiovascular-devices-market-analysis

Market Analysis by Device Type and End Users

By device type, therapeutic and surgical cardiovascular devices are expected to dominate the United States cardiovascular devices market, accounting for around 75% of the total share. These devices play a crucial role in the treatment of cardiovascular conditions such as coronary artery disease, heart failure, and cardiac arrhythmias. The increasing number of interventional cardiology procedures, along with the growing adoption of implantable cardiac devices and minimally invasive treatment solutions, continues to drive demand for therapeutic cardiovascular technologies across the country.

By end user, hospitals are expected to lead the market, capturing approximately 60% of the total share. Hospitals serve as the primary centers for complex cardiovascular procedures, including cardiac catheterization, heart valve interventions, and surgical treatments. Their access to advanced imaging systems, specialized cardiac care units, and highly skilled healthcare professionals enables them to manage a wide range of cardiovascular conditions effectively. Consequently, the concentration of advanced medical infrastructure within hospitals continues to strengthen their dominant position in the cardiovascular devices market.

View Full Report (All Data, In One Place):
https://www.vyansaintelligence.com/industry-report/united-states-cardiovascular-devices-market-analysis (Explore in-depth analyses, technological trends, and investment patterns.)

Major Cardiovascular Device Companies in the United States

Key companies contributing to innovation and competition in the market include:

• GE Healthcare
• Siemens Healthineers
• Stryker Corporation
• Medtronic plc
• Abbott Laboratories
• Boston Scientific Corporation
• Edwards Lifesciences Corporation
• Johnson & Johnson MedTech
• Philips Healthcare
• Terumo Corporation

United States Cardiovascular Devices Market Scope

By Device Type: Diagnostic and Monitoring, Therapeutic and Surgical

By Technology: Minimally Invasive and Transcatheter Technologies, Wearable Devices, Artificial Intelligence and Machine Learning, Robotic-Assisted Surgery

By Application: Coronary Artery Disease, Cardiac Arrhythmia, Heart Failure, Others

By End Users: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Care Settings

Browse More Reports on Medical Devices

France Neurodegenerative Disease Devices Market: Neurodegenerative disease devices market in France is estimated at USD 1.5 billion and is expected to grow to USD 2.5 billion by 2032. Moreover, the market is projected to register a CAGR of around 7.57% during 2026-32.

Germany Neurodegenerative Disease Devices Market: Neurodegenerative disease devices market in Germany is estimated at USD 1.74 billion and is expected to grow to USD 2.63 billion by 2032. Moreover, the market is projected to register a CAGR of around 6.08% during 2026-32.

US Wearable Medical Devices Market: Wearable medical devices market in the US is estimated at USD 12.02 billion in 2025 and is expected to grow to USD 36.93 billion by 2032. Moreover, the market is projected to register a CAGR of around 17.39% during 2026-32.

India Diabetes Monitoring Devices Market: Diabetes monitoring devices market in India is estimated at USD 2 billion in 2025 and is expected to grow to USD 2.8 billion by 2032. Also, the market is projected to register a CAGR of around 4.92% during 2026-32.

About Vyansa Intelligence

Vyansa Intelligence is a global market research and consulting firm dedicated to delivering strategic insights across high-growth and emerging industries worldwide. Our comprehensive research reports provide data-driven analysis of market trends, competitive landscapes, technological innovations, and regulatory developments shaping the global business environment. Supported by robust research methodologies, advanced forecasting models, and carefully validated primary and secondary data sources, Vyansa Intelligence empowers corporations, investors, and decision-makers to identify emerging opportunities, manage potential risks, and develop well-informed long-term strategies. We remain committed to delivering actionable market intelligence that supports sustainable business growth and strengthens competitive positioning in an increasingly dynamic marketplace.

Contact Us:

Vyansa Intelligence

Office: Office No.110, H-159, Sector 63, Noida, Uttar Pradesh - 201301, India
Contact No: +91 7065555003
Email: sales@vyansaintelligence.com
Website: vyansaintelligence.com

Logo: https://mma.prnewswire.com/media/2929228/Vyansa_Intelligence_Logo.jpg